American Univercity conducts a clinical trial of Glucose Differences Between the Left Arm and Right Arm in Diabetic Patients Using a Continuous Glucose Monitor

The University of the Pacific is conducting the clinical trial Glucose Differences Between the Left Arm and Right Arm in Diabetic Patients Using a Continuous Glucose Monitor.

Continuous glucose monitoring (CGM) is an emerging field for diabetes management. CGMs are small devices primarily placed on a patient's upper arm that allow providers and patients to individualize therapy by looking at real time glucose levels. While the accuracy of these devices is extensively researched, there are no large-scale studies evaluating the differences between left and right arm glucose readings in the diabetic population. Additionally cinnamon and aloe vera are supplements commonly used by diabetic patients to help improve glycemic control. However, there remains a shortage of studies researching the effects of cinnamon and aloe vera on diabetic patients' glycemic control.

The purpose of this study is to determine if there is a difference between glucose levels in the right arm and left arm in diabetic patients and to evaluate if cinnamon and aloe vera supplements impact glycemic control in diabetic patients.

Actual study start date is March 2021. The researchers expect to complete the study by February 2022.

One primary outcome measure is Difference in time-matched glucose levels between the right arm and the left arm.

Among the inclusion criteria are:

• Adult 18-65 years of age
• Diagnosed with type 2 diabetes
• Willing to wear CGM for 6 weeks on both arms
• Willing to come in for 4 office visits over 6 weeks
• Willing to consume assigned supplement twice a day for 4 weeks
• Willing to receive and respond to daily text messages or maintain a daily study log of supplement consumption
• Have active health insurance
• Willing to refrain from any heat therapy for the duration of the study
• Willing to refrain from taking any other supplements that are deemed by the investigator to alter glucose for the duration of the study
• Willing to refrain from consuming ascorbic acid and salicylic acid for the duration of the study due to a known interaction with CGMs
• Be able to self-monitor blood glucose with finger-stick method
• Have a baseline HbA1c > 6.5%

The location of the study is as follows (further details can be found here https://ichgcp.net/clinical-trials-registry/NCT04790760) Stockton, United States.